EAM
HUMA icon

Exos Asset Management’s Humacyte HUMA Stock Holding History

Exos Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$55K Sell
17,084
-1,525
-8% -$8.48K 0.03% 206
2022
Q1 		$131K Buy
18,609
+2,470
+15% +$14.4K 0.06% 178
2021
Q4 		$117K Sell
16,139
-2,803
-15% -$27.7K 0.06% 231
2021
Q3 		$220K Buy
18,942
+3,393
+22% +$38.8K 0.12% 238
2021
Q2 		$158K Buy
+15,549
New +$160K 0.08% 305

Other funds holding HUMA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Exos Asset Management's HUMA Position: Q2 2022 in Review

Exos Asset Management reduced its Humacyte (HUMA) stake by 8.2% in Q2 2022, selling an estimated $8.48K and leaving 17,084 shares worth $55K. The position accounts for 0.03% of the portfolio, ranked #206.

Exos Asset Management first reported a position in HUMA in Q2 2021 and has held it in 5 quarters since. The position peaked at $220K in Q3 2021. 78 funds tracked by Wall St. Rank hold HUMA as of Q2 2022.

  • Exos Asset Management held 17,084 shares of Humacyte worth $55K as of Q2 2022.
  • Exos Asset Management sold 1,525 Humacyte shares in Q2 2022, an estimated $8.48K.
  • Humacyte made up 0.03% of Exos Asset Management's portfolio in Q2 2022, its #206 holding.
  • Exos Asset Management first reported a position in Humacyte in Q2 2021 and has held it in 5 quarters since.
  • Exos Asset Management's Humacyte position peaked at $220K in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Humacyte as of Q2 2022.

Based on Exos Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.